Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; Company to conduct additional preclinical study focused on lung cancer cell linesGRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-dri ...

New York, May 22, 2025 (GLOBE NEWSWIRE) -- PESG Research today announced the release of a report examining Silexion Therapeutics, an innovative biotechnology company developing unique RNA interference (RNAi) therapies targeting KRAS-driven cancers. The below report explores the company's disruptive technological approach, recent scientific milestones, and potential implications for cancer treatment strategies, in the fast growing precision oncology market. Executive Summary The precision oncology landscape ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a yearGRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driv ...

Financial Performance - Silexion raised over $9 million in gross funds during Q1 2025, strengthening its financial position[1] - The company reported a net loss of $1.7 million for Q1 2025, compared to a net loss of $1.4 million in Q1 2024, primarily due to increased general and administrative expenses[7] - Cash and cash equivalents increased to $6.2 million as of March 31, 2025, up from $1.2 million as of December 31, 2024[7] - Total operating expenses for Q1 2025 were $1.7 million, an increase from $1.3 million in the same period of 2024[7] - Research and development expenses decreased to $0.6 million in Q1 2025 from $1.0 million in Q1 2024, reflecting reduced subcontractor costs[7] - Total assets increased to $8.3 million as of March 31, 2025, compared to $2.9 million as of December 31, 2024[9] Product Development - SIL204 demonstrated a ~70% reduction in tumor cell numbers in the AsPC-1 model and ~80% reduction in the BxPC-3 model by day 28 in preclinical studies[3] - The company unveiled an expanded dual-route development strategy for SIL204, targeting both primary tumors and metastases, with clinical trials planned to start in the first half of 2026[3] - Silexion announced a strategic collaboration with Catalent for formulation development and clinical manufacturing activities for SIL204[3] - The company completed a public offering raising approximately $5.0 million in gross proceeds during Q1 2025[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File No. 001-42253 SILEXION THERAPEUTICS CORP (Exact name of registrant as specified in its charter) | Cayman Islands N/A | | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 12 Abba Hillel Road | | | Ramat-Gan, Israel 5250606 | | | (Address of Principal Executive Offices, including zip code) | | | +972-3-7564999 | | | (Registrant's telephone numbe ...

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported i ...

Grand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics. Under the agreement, Catalent will conduct formulation development and clinical manufactu ...

Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical TrialsGrand Cayman, Cayman Islands, April 23, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical deve ...

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates systemic administration to target metastatic progression with intratumoral administration to focus on primary tumors, offering a comprehensive app ...

Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the PresentationGrand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies fo ...